Promising fusion protein design to target the U87 MG glioma cell line

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 4, 2011, Pages 935-937

  Jing, Chen ^a   Yuan, Lin ^a   Xingguo, Pan ^a   Zhijie, Huang ^a   Zai xi, Chen ^a   Ru, Zhang ^a   Jian, You ^b  

^a The General Hospital of Chengdu Military Area   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Fusion proteins; Glioma therapy; Momoclonal antibodies; Toxins

Indexed keywords

EID: 84856287129     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Aburatani T, Ueda H, Nagamune T (2002). Importance of a CDRH3 basal residue in VH/VL interaction of human antibodies. J. Biochem, 132, 775-785.
2. Binz HK, Amstutz P, Plückthun A (2005). Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol, 23, 1257-1267
3. Ewert S, Huber T, Honegger A, et al (2003). Biophysical properties of human antibody variable domains. J Mol Biol, 325, 531-553
4. Fujimori K, Fisher DR, Weinstein JN (1991). Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution. Cancer Res, 51, 4776-4784.
5. Holliger P, Hudson P (2005). Engineered antibody fragments and the rise of single domains. Nat. Biotechnol, 23, 1126-1136.
6. Kohler G, Milstein C (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495-497.
7. Qiu XQ, Wang H, Cai B, et al (2007). Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat Biotechnol, 25, 921-929.
8. Zhen ZP, Zhang J, Zhang SY (2009). Development of a novel small antibody that retains specificity for tumor targeting. J Exp Clin Cancer Res, 30, 59.
9. Zülch KJ, Brain Tumors (1986). Their biology and pathology. Berlin-Heidelberg-New York: Springer Verlag.